NCT06043466View on ClinicalTrials.gov

A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 11, 2023

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Colorectal CancerEsophagus CancerGastric CancerPancreas CancerNon-small Cell Lung CancerBreast CancerBile Duct Cancer
Interventions
BIOLOGICAL

CEA-targeted CAR-T cells

Administration method: intravenous infusion； Subjects will receive conditioning therapy by Fludarabine and Cyclophosphamide before cell infusion.

Trial Locations (2)

Unknown

RECRUITING

The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

RECRUITING

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

All Listed Sponsors
collaborator

Zhejiang University

OTHER

lead

Chongqing Precision Biotech Co., Ltd

INDUSTRY